Stock Analiz

Relay Therapeutics, Inc. (RLAY) financials: revenue, earnings and cash flow

Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$276M, a net margin of -1800.6%; the best year in this period was 2020 with -$52M.

Over the twelve months to September 30, 2026, revenue was $10M and net income -$294M.

Free cash flow was -$236M in fiscal 2025 and positive in 0 of the 7 years shown.

The diluted share count rose 4873% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2020: $83M20202021: $3M20212022: $1M20222023: $26M20232024: $10M20242025: $15M2025$15M
Net income
2019: -$75M20192020: -$52M20202021: -$364M20212022: -$291M20222023: -$342M20232024: -$338M20242025: -$276M2025-$276M
Free cash flow
2019: -$74M20192020: -$104M20202021: -$78M20212022: -$239M20222023: -$304M20232024: -$251M20242025: -$236M2025-$236M
EPS (diluted)
2019: $-21.8220192020: $-5.4020202021: $-3.8220212022: $-2.5920222023: $-2.7920232024: $-2.3620242025: $-1.612025$-1.61

Income statement

Fiscal yearTTM2025202420232022202120202019
Revenue$10M$15M$10M$26M$1M$3M$83M—
Gross profit————————
Operating income-$320M-$303M-$372M-$373M-$299M-$365M-$56M-$84M
Net income-$294M-$276M-$338M-$342M-$291M-$364M-$52M-$75M
EPS (diluted)$-1.50$-1.61$-2.36$-2.79$-2.59$-3.82$-5.40$-21.82
R&D$280M$261M$319M$330M$246M$173M$100M$70M
Revenue growth—+53.4%−60.8%+1749.8%−54.4%−96.3%——

Cash flow

Fiscal yearTTM2025202420232022202120202019
Operating cash flow-$214M-$235M-$249M-$300M-$229M-$74M-$102M-$66M
Capital spending-$1000-$410000-$2M-$4M-$9M-$3M-$2M-$8M
Free cash flow-$214M-$236M-$251M-$304M-$239M-$78M-$104M-$74M
Dividends paid$0$0$0$0$0$0$0$0
Buybacks————————
Stock-based pay$43M$62M$94M$86M$56M$48M$32M$4M

Balance sheet

Fiscal yearTTM2025202420232022202120202019
Cash—$84M$124M$144M$152M$280M$448M$42M
Debt—$32M$49M$53M$58M$23M$24M$25M
Equity—$567M$778M$752M$950M$898M$763M-$180M
Total assets—$621M$871M$844M$1.1B$1.0B$800M$393M
Shares (diluted)194M172M143M123M112M95M43M3M

Margins and returns

Fiscal yearTTM2025202420232022202120202019
Gross margin————————
Operating margin-3094.6%-1971.6%-3722.1%-1460.1%-21670.9%-12040.2%-67.5%—
Net margin-2837.0%-1800.6%-3374.7%-1338.7%-21036.1%-12012.9%-63.4%—
FCF margin-2067.8%-1536.1%-2509.5%-1191.7%-17273.9%-2571.1%-126.3%—
ROIC—-39.9%-35.6%-36.6%-23.5%-31.3%-5.6%—
ROE—-48.8%-43.4%-45.5%-30.6%-40.5%-6.9%41.7%

Frequently asked questions

What is Relay Therapeutics’s annual revenue?

$15M in fiscal 2025 and $10M over the twelve months to September 30, 2026.

How much profit does Relay Therapeutics make?

Net income was -$276M in fiscal 2025 (net margin -1800.6%).

Is Relay Therapeutics’s revenue growing?

Yes: revenue rose 53.4% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.